Resistance of Helicobacter pylori to antibiotics and its impact on treatment options

2001 ◽  
Vol 4 (3) ◽  
pp. 178-186 ◽  
Author(s):  
Francis Mégraud
Keyword(s):  
Helicobacter Pylori ◽  
Treatment Options ◽  
Impact On Treatment

scholarly journals Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication

2020 ◽  
Vol 20 (3) ◽  
pp. 218-224
Author(s):  
Hyun Soo Kim ◽  
Hyuk Yoon ◽  
Dong Woo Shin ◽  
Dong Jun Oh ◽  
Mingu Kwon ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Rescue Therapy ◽  
Treatment Options ◽  
Treatment Protocol ◽  
Resistance Rate ◽  
Quadruple Therapy ◽  
Minimal Inhibitory Concentrations ◽  
Intention To Treat ◽  
H Pylori ◽  
Triple Regimen

Background/Aims: The treatment options for Helicobacter pylori (<i>H. pylori</i>) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are new antibiotics. The aim of this study was to evaluate the efficacy and safety of adding rifaximin to the standard triple regimen and of a rifabutin-based triple regimen as a rescue therapy for <i>H. pylori</i> eradication.Materials and Methods: We enrolled 27 <i>H. pylori</i>-positive patients who were treated with a proton pump inhibitor, amoxicillin, clarithromycin, and rifaximin for 14 days. <i>H. pylori</i> eradication was assessed by a <sup>13</sup>C-urea breath test performed 4 weeks after therapy completion. The efficacy of the therapy was based on intention-to-treat (ITT) and per-protocol (PP) analysis. We also investigated the resistance rate, compliance, and side effects associated with rifaximin therapy. Minimal inhibitory concentrations and resistance to rifabutin were evaluated using the agar dilution method.Results: Of the 27 patients, 22 completed the treatment protocol with 100% compliance; five patients withdrew. The ITT and PP eradication rates for the rifaximin-containing quadruple therapy were 70.4% (19/27) and 86.3% (19/22), respectively. Adverse events were observed in five of 22 patients (22.7%). The resistance rates to rifaximin and rifabutin were 66.7% (2/3) and 0% (0/3), respectively.Conclusions: The findings of this study show the limitations of rifaximin-based quadruple therapy and suggest the benefits of a rifabutin-based rescue regimen in South Korea.

scholarly journals Mucosa-Associated Lymphoid Tissue Lymphoma of the Lacrimal Gland: Sustained Remission after Eradication of Helicobacter Pylori Infection

2011 ◽  
Vol 2011 ◽  
pp. 1-4
Author(s):  
Mohammed Hasosah ◽  
Abdullah Baothman ◽  
Mohamed Satti ◽  
Suzanne Kutbi ◽  
Khaled Alghamdi ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Malt Lymphoma ◽  
Lacrimal Gland ◽  
Lymphoid Tissue ◽  
Treatment Options ◽  
Disease Process ◽  
Helicobacter Pylori Infection ◽  
Surgical Removal ◽  
Sustained Remission ◽  
Non Hodgkin Lymphoma

Mucosa-associated lymphoid tissue (MALT) lymphoma is the third most common non-Hodgkin lymphoma, and it is strongly associated with helicobacter pylori infection of the stomach. MALT lymphoma of the lacrimal gland usually presents as a localized disease process in extranodal tissues. The treatment options of MALT lymphoma of the lacrimal gland chiefly include radiation of the tumor, chemotherapy, surgical removal, or a combination of these strategies. We report a case of localized MALT lymphoma of the lacrimal gland, with prolonged sustained remission after eradication of gastric Helicobacter pylori (H. Pylori) infection. He sustains in remission of lacrimal MALT lymphoma for four years without chemotherapy or radiotherapy.

Treatment options in helicobacter pylori negative alkaline gastritis

2001 ◽  
Vol 33 ◽  
pp. A110
Author(s):  
L. Santarelli ◽  
M. Candelli ◽  
M. Gabrielli ◽  
F. Cremonini ◽  
E.C. Nista ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Treatment Options

Treatment options for Helicobacter pylori infection in the elderly

Aging Health ◽  
2006 ◽  
Vol 2 (4) ◽  
pp. 661-668 ◽  
Author(s):  
Alberto Pilotto ◽  
Marilisa Franceschi ◽  
Francesco Perri ◽  
Giuseppe Orsitto ◽  
Francesco Di Mario
Keyword(s):  
Helicobacter Pylori ◽  
Treatment Options ◽  
The Elderly ◽  
Helicobacter Pylori Infection

scholarly journals Direct detection of Helicobacter pylori from biopsies of patients in Lagos, Nigeria using real-time PCR—a pilot study

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
A. Ajayi ◽  
T. Jolaiya ◽  
S. I. Smith
Keyword(s):  
Helicobacter Pylori ◽  
16S Rrna ◽  
Real Time ◽  
Real Time Pcr ◽  
Direct Detection ◽  
Low Cost ◽  
Treatment Options ◽  
Combined Cycle ◽  
Diagnostic Methods ◽  
H Pylori

Abstract Objective Prompt diagnosis of Helicobacter pylori infection is essential for proper treatment and eradication of the pathogen because prolonged infection could lead to gastric cancer. Sensitive and cost effective diagnostic methods are key to guiding treatment options that will reduce mortality. This study was aimed at detecting H. pylori from biopsies of peptic ulcer patients. Real-time PCR using TaqMan and EvaGreen assays targeting 16S rRNA and ureA genes were used to detect H. pylori DNA extracted from 40 biopsy samples comprising 20 biopsies obtained from the antrum and 20 from the corpus of 20 patients undergoing endoscopy for duodenal ulcer investigation in Lagos, Nigeria. Results H. pylori was detected in 80% of the biopsy samples by combined cycle threshold (Ct) and melting temperature (Tm) values. Mean Ct value for ureA gene ranged from 21.40 to 37.53 and 22.71 to 35.44 for 16SrRNA gene. Average melting temperatures (Tm) of 81.57 and 82.90 °C among amplicons of ureA and 16S rRNA were observed respectively. H. pylori DNA was generally detected in biopsies collected from antrum and corpus. Real-time PCR in the diagnosis of H. pylori can be considered a simple, low cost and efficient alternative or addition to the gold standard.

scholarly journals Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 153
Author(s):  
Isabel Villegas ◽  
María Ángeles Rosillo ◽  
Catalina Alarcón-de-la-Lastra ◽  
Victoria Vázquez-Román ◽  
Maria Llorente ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Bacterial Resistance ◽  
Drug Product ◽  
Treatment Options ◽  
Systemic Exposure ◽  
Bacterial Count ◽  
Current Treatment ◽  
Gastric Ulcers ◽  
Predisposing Factor ◽  
H Pylori

Helicobacter pylori is the main pathogen responsible for gastric ulcers and a predisposing factor of stomach cancer. Although current treatment is usually successful, it requires high doses and frequent administration. An innovative mucoadhesive system (Mucolast®) loaded with amoxicillin and clarithromycin is proposed to improve the efficacy of treatment against H. pylori. The drug product was optimized based on its viscoelastic properties to obtain long-term stability of the vehicle. The drug release mechanisms were different for both antibiotics based on their solubilization status. A systemic and stomach pharmacokinetic profile was obtained after three different doses were administered to mice, obtaining similar systemic exposure levels but an increase in drug concentration in the stomach. The efficacy results in mice infected with H. pylori also demonstrated the superiority of the antibiotics when administered in Mucolast®, as shown by the bacterial count in stomach tissue and under histopathological and biochemical evaluation. The proposed treatment was efficacious and safe and is presented as a realistic alternative to current treatment options to improve patient compliance and to reduce bacterial resistance.

Sign in / Sign up

Export Citation Format

Share Document